112 related articles for article (PubMed ID: 15490332)
41. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
Bai SX; Wang YL; Qin L; Xiao ZJ; Herva R; Piao YS
Reproduction; 2005 Jan; 129(1):103-13. PubMed ID: 15615902
[TBL] [Abstract][Full Text] [Related]
42. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
43. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells.
Nilsson UW; Garvin S; Dabrosin C
Breast Cancer Res Treat; 2007 May; 102(3):253-61. PubMed ID: 17031577
[TBL] [Abstract][Full Text] [Related]
44. Flavonoids of Helichrysum compactum and their antioxidant and antibacterial activity.
Süzgeç S; Meriçli AH; Houghton PJ; Cubukçu B
Fitoterapia; 2005 Mar; 76(2):269-72. PubMed ID: 15752647
[TBL] [Abstract][Full Text] [Related]
45. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
46. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
[TBL] [Abstract][Full Text] [Related]
47. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model.
Karagiannis ED; Popel AS
J Theor Biol; 2006 Jan; 238(1):124-45. PubMed ID: 16005020
[TBL] [Abstract][Full Text] [Related]
48. 3,4,5-trihydroxybenzaldehyde from Geum japonicum has dual inhibitory effect on matrix metalloproteinase 9; inhibition of gelatinoytic activity as well as MMP-9 expression in TNF-alpha induced HASMC.
Suh SJ; Cho KJ; Moon TC; Chang HW; Park YG; Kim CH
J Cell Biochem; 2008 Oct; 105(2):524-33. PubMed ID: 18773430
[TBL] [Abstract][Full Text] [Related]
49. A flavone from Manilkara indica as a specific inhibitor against aldose reductase in vitro.
Haraguchi H; Hayashi R; Ishizu T; Yagi A
Planta Med; 2003 Sep; 69(9):853-5. PubMed ID: 14598214
[TBL] [Abstract][Full Text] [Related]
50. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
51. The effect of sativan from Viola verecunda A. Gray on the expressions of matrix metalloproteinase-1 caused by ultraviolet irradiated cultured primary human skin fibroblasts.
Moon HI; Kim EJ; Lee J; Lee HK; Chung JH
J Ethnopharmacol; 2006 Mar; 104(1-2):12-7. PubMed ID: 16207520
[TBL] [Abstract][Full Text] [Related]
52. Buddleja officinalis inhibits high glucose-induced matrix metalloproteinase activity in human umbilical vein endothelial cells.
Lee YJ; Kang DG; Kim JS; Lee HS
Phytother Res; 2008 Dec; 22(12):1655-9. PubMed ID: 18688800
[TBL] [Abstract][Full Text] [Related]
53. High molecular weight coffee melanoidins are inhibitors for matrix metalloproteases.
De Marco LM; Fischer S; Henle T
J Agric Food Chem; 2011 Nov; 59(21):11417-23. PubMed ID: 21961901
[TBL] [Abstract][Full Text] [Related]
54. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
[TBL] [Abstract][Full Text] [Related]
55. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
[TBL] [Abstract][Full Text] [Related]
56. Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates.
Makowski GS; Ramsby ML
Clin Chim Acta; 2005 Aug; 358(1-2):182-91. PubMed ID: 15921672
[TBL] [Abstract][Full Text] [Related]
57. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
58. The matrix metalloproteinase system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
[TBL] [Abstract][Full Text] [Related]
59. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
60. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
